Dermatitis : contact, atopic, occupational, drug最新文献

{"title":"A Cross-Specialty Matched Comparison: Non-Dermatologists More Likely to Diagnose Dermatitis in Skin of Color Patients.","authors":"Chidubem A V Okeke, Matthew Ponzini, Sydney D Sullivan, Lauren W Hastings, Olivia Keller, Peggy A Wu","doi":"10.1089/derm.2024.0459","DOIUrl":"10.1089/derm.2024.0459","url":null,"abstract":"<p><p><u><b><i></i></b></u> In this study, we assessed the demographics of patients diagnosed with dermatitis in internal medicine, dermatology, or family medicine in the University of California, Davis hospital system. Characteristics between the specialties were compared using logistic regression in R®. We found that underrepresented racial and ethnic groups are more likely to be diagnosed with dermatitis by a non-dermatologist and that MediCal and Medicare beneficiaries were more likely to be seen by dermatology than internal medicine or family medicine for dermatitis. Additional studies should explore the causality of the associations noted in this investigation.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"556-558"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143451246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Dupilumab-Induced Facial Flushing after Alcohol Consumption: Two Case Reports and Review of the Literature.","authors":"Omar Al-Wattar-Ceballos, Juan Ruiz Sánchez, Irene Albert-Cobo, Juan Francisco Silvestre Salvador","doi":"10.1089/derm.2024.0522","DOIUrl":"10.1089/derm.2024.0522","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"530-532"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential for Allergic Contact Dermatitis in Popular Depilatory Wax Hair Removal Practices and Ingredients.","authors":"Shaina E George, Mykayla Sandler, JiaDe Yu","doi":"10.1089/derm.2024.0236","DOIUrl":"10.1089/derm.2024.0236","url":null,"abstract":"<p><p><u><i></i></u> Allergic contact dermatitis (ACD) is a type IV delayed hypersensitivity reaction that can commonly arise from exposure to allergens in personal care and cosmetic products. Depilatory waxing, a common hair removal practice, involves the use of various products that may contain potential contact allergens. There is limited literature discussing ACD to hair removal products. We aim to discover the most common allergens prevalent in depilatory waxing products used in a popular wax center in the United States and those found in online marketplaces. Through communication with the salon staff, we reviewed the involved products and analyzed all ingredients for common allergens. We also conducted an online search to examine the ingredients and the most common allergens of the top 10 bestselling wax strips across four selected online marketplaces (CVS, Amazon, Walmart, and Walgreens). The final query of online products consisted of 12 distinct wax products and 10 postwax products. Among the products used in the salon, the most common allergens were vitamin E, colophony, botanicals, fragrance, beeswax/propolis, and color additives, in descending order. The most frequent allergens commonly encountered in online wax products included color additives, found in 67% (8/12) products, followed by botanicals and colophony, both present in 58% (7/12) products. In the postwax products, the most frequent allergen was vitamin E present in 100% (10/10) of the products, followed by fragrance (8/10). Although these allergens do not frequently cause ACD, it remains crucial to identify and note them in hair removal products to address any potential cases. Raising awareness of these allergens in all steps of hair removal can help ensure the safety and comfort of patients undergoing waxing treatments.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"447-451"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contact Dermatitis of the Scalp: An Evaluation of Allergens Among Textured Haircare Products.","authors":"Kimberly N Williams, Chika Nwosu, Antonella Tosti","doi":"10.1089/derm.2024.0469","DOIUrl":"10.1089/derm.2024.0469","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"532-535"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study.","authors":"Elena Pezzolo, Maddalena Napolitano, Alessandra Narcisi, Luigi Gargiulo, Ilaria Trave, Mariateresa Rossi, Rosanna Satta, Francesca Caroppo, Roberta Pandolfi, Alba Guglielmo, Katiuscia Nan, Cataldo Patruno, Luigi Naldi","doi":"10.1089/derm.2024.0335","DOIUrl":"10.1089/derm.2024.0335","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"542-545"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time of Day of Biological Treatment Administration and Outcomes in Atopic Dermatitis: Results from a Preliminary Retrospective Study.","authors":"Alessandro Borghi, Maria Elena Flacco, Chiara Bocchi, Natale Schettini, Edoardo Arlotti, Roberto Manfredini, Monica Corazza","doi":"10.1089/derm.2024.0282","DOIUrl":"10.1089/derm.2024.0282","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Growing evidence on chronotherapy supports administering treatments according to endogenous biological rhythms. <u><b><i>Objectives:</i></b></u> To evaluate whether the administration time of dupilumab affects its effectiveness in patients with atopic dermatitis (AD), by virtue of the circadian oscillations of immune system activity. <u><b><i>Methods:</i></b></u> This retrospective study included all adult patients with AD treated with dupilumab from January 2020 to January 2024 at our unit. Data recorded at baseline (T0) and at the 16-week-treatment visit (T16) included itch severity, sleep disturbance, Eczema Area and Severity Index, Patient-Oriented Eczema Measure, Dermatology Life Quality Index, and immunoglobulin E levels. Therapeutic response was compared between two groups, based on injection time, that is, between 12:00 a.m. and 12:00 p.m. versus between 12:00 p.m. and 12:00 a.m. <u><b><i>Results:</i></b></u> Fifty-three patients were included, of whom 21 took dupilumab between 12:00 a.m. and 12:00 p.m. and 32 between 12:00 p.m. and 12:00 a.m. All clinical parameters improved from T0 to T16, without significant differences between groups. However, there was a greater improvement in these parameters in subjects taking dupilumab between 12:00 a.m. and 12:00 p.m., compared with the others. <u><b><i>Conclusions:</i></b></u> These preliminary results suggest a difference in therapeutic response to dupilumab based on the administration time, leading to potential optimization of its efficacy. Further studies on larger samples are needed.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"490-499"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarification and Modification of the International Contact Dermatitis Research Group Classification of Patch Test Reactions on Behalf of the International Contact Dermatitis Research Group.","authors":"Magnus Bruze, Cecilia Svedman","doi":"10.1089/derm.2024.0365","DOIUrl":"10.1089/derm.2024.0365","url":null,"abstract":"<p><p><u><i><b></b></i></u> The first ICDRG (International Contact Dermatitis Research Group) classification of patch test reactions was published in 1970. With this classification, many weak reactions were classified as allergic reactions. A second classification was therefore implemented one decade later on behalf of the ICDRG and the North American Contact Dermatitis Group. This classification was adopted by the European Society of Contact Dermatitis. Evaluation of the significance of the results of various studies on patch test reading demonstrated that a new ICDRG classification of patch test reactions was needed. A classification system should not be based on the exclusive presence/absence of papules and vesicles, i.e., the words \"possibly papules/vesicles\" allow for the unavoidable variation in reading among experts. Dermatologists are not reading patch test reactions in a uniform way due to lack of a clear definition of the threshold between weak allergic and doubtful reactions. A new ICDRG classification with clarifications and modifications of the old one is presented.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"440-446"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Quality of Life in Patients With Atopic Dermatitis: A Case-Control Study.","authors":"Manal El Idrissi, Ines Lahouel, Mariem Kacem, Khaoula Trimeche, Hichem Belhadjali, Yosra Soua, Monia Youssef, Jameleddine Zili","doi":"10.1177/17103568251368351","DOIUrl":"https://doi.org/10.1177/17103568251368351","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Atopic dermatitis (AD) is a chronic, itchy inflammatory disease that significantly affects quality of life (QoL). Assessing this impact is essential for optimal management. <u><b><i>Objective:</i></b></u> The aim of the study was to evaluate the impact of AD on QoL in affected patients and their families. <u><b><i>Methods:</i></b></u> We conducted a case-control study at the Monastir Dermatology Department over 4 months (September-December 2022), including 100 patients with the disease and 100 controls. QoL was assessed using Dermatology Life Quality Index (DLQI) (>15 years), Children's Dermatology Life Quality Index (CDLQI) (5-15 years), IDQOL (<5 years), and Dermatitis Family Impact (DFI) for families. <u><b><i>Results:</i></b></u> The median age of patients and controls was 13.5 years, with a female predominance (F/H ratio = 1.32). The median onset age was 5 years. QoL was significantly worse in patients with AD and their families. CDLQI and DLQI showed moderate positive correlations with Scoring Atopic Dermatitis Index (SCORAD) (<i>P</i> = 0.004; <i>r</i> = 0.434 and <i>P</i> = 0.033; <i>r</i> = 0.322), while DFI had a strong correlation (<i>P</i> < 0.001; <i>r</i> = 0.575), reflecting the family burden. Beyond disease severity, QoL was influenced by pruritus intensity, socioeconomic status, environmental factors, and eczema extent, topography, and appearance. <u><b><i>Conclusions:</i></b></u> AD significantly impacts patients' and families' QoL. Specific QoL assessment scales are essential for optimizing management.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weapons of War and Dermatology: A Comprehensive Review of Cutaneous Manifestations From Chemical Warfare Agents, Part II: Nerve Agents, Cyanides, and Riot Control Agents.","authors":"William J Nahm, Emily C Milam, David E Cohen","doi":"10.1177/17103568251367715","DOIUrl":"https://doi.org/10.1177/17103568251367715","url":null,"abstract":"<p><p><u><b><i></i></b></u> This second installment in a two-part comprehensive review explores chemical warfare agents that primarily cause systemic toxicity with secondary cutaneous manifestations: nerve agents, cyanides, and riot control agents (RCAs). While these agents are primarily known for their systemic effects, their dermatological manifestations can provide critical diagnostic clues in exposure scenarios. Part II examines the G-series, V-series, GV-series, and Novichok nerve agents; various cyanide compounds; and both historical and modern RCAs. For each agent class, the review details their historical contexts, physicochemical properties, mechanisms of action, dermatological manifestations, and current treatment approaches. The widespread use of RCAs in civilian law enforcement underscores the practical relevance of understanding these compounds. Additionally, despite international prohibitions, some of these agents continue to pose threats in modern conflicts and targeted assassinations. The review highlights the crucial role dermatologists can play in multidisciplinary response teams, as recognizing characteristic cutaneous changes may facilitate rapid diagnosis and life-saving intervention. Future preparedness efforts should incorporate specialized training for health care providers, emphasizing the distinct dermatological presentations of these agents.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming Atopic Dermatitis Management: Probiotics as a Game-Changer in Immune Modulation-A Double-Blind, Placebo-Controlled Clinical Trial.","authors":"Caterina Mariarosaria Giorgio, Gaetano Licata, Raffaele Sorbo, Emilia Galdiero, Federica Carraturo, Eugenia Veronica Di Brizzi, Anna Balato, Dario De Brasi, Giuseppe Argenziano, Igeamartina Madonna, Edi Mattera","doi":"10.1177/17103568251367725","DOIUrl":"https://doi.org/10.1177/17103568251367725","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation and microbiota imbalances. It affects millions worldwide, leading to significant morbidity and reduced quality of life. The disease is marked by intense pruritus, xerosis, and eczematous lesions, often accompanied by psychological distress and sleep disturbances. Recent research has established a strong association between gut dysbiosis and AD pathogenesis, suggesting that interventions targeting the gut microbiota may offer therapeutic benefits. <u><b><i>Objective:</i></b></u> This study aimed to evaluate the effects of a high-dose multistrain probiotic formulation, DSF Formulation®, on disease severity and immune modulation in adult patients with moderate-to-severe AD. <u><b><i>Methods:</i></b></u> A double-blind, randomized, placebo-controlled trial was conducted, enrolling 80 adult patients diagnosed with AD. Participants were randomly assigned to receive either DSF Formulation® or a placebo for 60 days. Clinical outcomes were assessed using Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Dermatology Life Quality Index (DLQI) scoring systems, while immunological parameters were evaluated by measuring cytokine levels (IL-4, IL-10, and TGF-β) via enzyme-linked immunosorbent assay. <u><b><i>Results:</i></b></u> Probiotic supplementation resulted in a significant reduction in SCORAD, EASI, and DLQI scores compared to the placebo group (<i>P</i> < 0.05). Additionally, a substantial decrease in IL-4 levels was observed in the probiotic-treated group, alongside a significant increase in IL-10 and TGF-β levels (<i>P</i> < 0.05), indicating a shift towards an anti-inflammatory immune response. <u><b><i>Conclusion:</i></b></u> These findings suggest that DSF Formulation® may serve as an effective adjunctive therapy for AD by modulating the gut microbiota and promoting an anti-inflammatory immune response. Furthermore, studies are warranted to confirm these results, assess long-term clinical implications, and determine the optimal probiotic formulations for therapeutic use.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}